Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma

Podobne zapisy

• Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
  od: An, Ning, i wsp.
  Wydane: (2019)
• Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
  od: Chen, Yanxin, i wsp.
  Wydane: (2019)
• Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
  od: Liu, Jing, i wsp.
  Wydane: (2016)
• The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
  od: Hung, Ming-Szu, i wsp.
  Wydane: (2016)
• Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
  od: Wen, Miaomiao, i wsp.
  Wydane: (2018)